



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

1. Name of Inspector from whom received : Mrs. Zarzokimi, Assistant Drugs Inspector (Food and Drugs)
C.M.O. Office,
Champhai-796321 Mizoram
2. Serial No. and date of Inspector's memorandum : 103/IPA-CPI/II-25 , 28-MAY-2025
3. Number of Sample : NIL
4. Date of receipt : 16-JUN-2025
5. Names of drugs purporting to be contained in the sample : CILNIDIPINE TABLETS IP 5 mg (CETANIL 5 mg)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-26/0698	GUW/LS/2025-26/695	2408000935	Aug-2024 Jul-2026	NA	M/s. Alembic Pharmaceuticals Ltd.,, Samardung Basti, Karek Block, Namthang ilaka, South Sikkim-737126

6. Condition of seals on : Seals were intact & identical to the specimen impression of the seal received from Drugs Inspector
[the packet or on portion of sample or container]

7. Result of test or analysis with protocols or test or analysis applied : Please see below

Date of Testing : From 04-Aug-2025 To 10-Sep-2025

COMPOSITION : Each film coated tablet is purported to contain Cilnidipine IP 5 mg.

Protocol Applied : I.P.2022

Sr No.	Test Name	Result	Limits
1	Description	Brown colored, round, bi-convex, film coated tablets, in blister pack.	NA
2	Identification	Gives positive test for Cilnidipine.	NA
3	Average Weight	0.1455 g	NA
4	Dissolution	Complies.	NLT 70 % of claim

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Cilnidipine	4.89 mg/Tablet	5 mg/Tablet	97.8	90 % to 110 %	I.P.2022

In the opinion of the undersigned the sample referred to above is of standard quality as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P.2022 in respect of test performed.

Date: 16-SEP-2025

Rinku Kalita

GOVERNMENT ANALYST

Rinku Kalita
Government Analyst
R.D.T.L., Guwahati-22

-----END OF REPORT-----

